Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01835236 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (NCT01835236)

Trial Description
In HER2-positive metastatic breast cancer, trastuzumab (Herceptin®;Genentech, Inc.) based treatment is the standard of care as long as there are no contraindications to trastuzumab. Frequently, trastuzumab is being combined with taxanes in the first-line setting. However, since therapy with trastuzumab is active even in the absence of chemotherapy in HER2-positive MBC, the optimal treatment strategy either in combination or in sequence with chemotherapy is still under debate.

This randomized phase II trial is studying a new strategy for the treatment of metastatic breast cancer with HER2-positive. First-line treatment consists of trastuzumab and pertuzumab (Perjeta®; Genentech, Inc.), a treatment without chemotherapy. In case of disease progression, chemotherapy with ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) is then performed as second-line treatment. Third-line and further line therapies are performed according to the physician’s discretion. If this new therapeutic strategy is as effective and better tolerated than the conventional strategy, this would mean a serious breakthrough in the treatment of HER2-positive metastatic breast cancer.

This trial is sponsored by Swiss Group for Clinical Cancer Research. [1]

Study Data

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 28, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar